Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
NEW YORK, July 28, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan, Inc. (NYSE:AGN) from February 25, 2014 through April 21, 2014, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Allergan investors under the federal securities laws.
To join the Allergan class action, go to http://rosenlegal.com/cases-1156.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The class action asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 arising from the 2014 attempted acquisition of Allergan by Valeant and its affiliates. The complaint alleges that certain Defendants traded on material non-public information regarding the proposed acquisition, and as a result, Class members that sold Allergan call options, purchased Allergan put options and/or sold Allergan equity forward contracts during the Class Period did so at prices that did not reflect the material nonpublic information known to Defendants. In this action, Plaintiff seeks an award of damages, and prejudgment interest, to Plaintiff and other Class members.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1156.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
